Clinical trials: Recurrent Small Cell Lung Cancer
Lung Cancer
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. ZD 1839 may interfere with the growth factor and stop the tumor from growing.
- Trial name
- NCT00006048
- Testing
- cisplatin, gefitinib, gemcitabine hydrochloride
- Where
- United States
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Long-term Observation PMS for Afatinib
In Japan, post-approval execution of post marketing surveillance (PMS) is requested by the Japanese Pharmaceutical Affairs Law (J-PAL) in order to accumulate safety and efficacy data for reexamination.
- Trial name
- NCT02131259
- Testing
- Afatinib dimaleate
- Where
- 432 sites in Japan
- Volunteers
- 1,605 people
- Sponsor
- Boehringer Ingelheim
Small Cell Lung Cancer (SCLC)
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
- Trial name
- DeLLphi-304 (NCT05740566)
- Testing
- Tarlatamab, Lurbinectedin, Topotecan
- Where
- 223 sites in United States, Argentina and 29 more
- Volunteers
- 509 people
- Sponsor
- Amgen
Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
This example study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or…
- Conditions
- Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, Extensive-stage SCLC
- Trial name
- NCT07744256
- Testing
- EB-DART-NK01, Lymphodepleting chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Lung Cancer
Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, and paclitaxel poliglumex, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00551733
- Testing
- carboplatin, paclitaxel, paclitaxel poliglumex
- Where
- 41 sites in United States
- Volunteers
- 450 people
- Sponsor
- CTI BioPharma
Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Conventional biopsy and surgical tumor resection are invasive procedures that capture only one instance of the progression of the tumor. However, the genome of tumor is not static, but it is constantly altered during treatment.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma
- Trial name
- NCT04490564
- Testing
- PD-L1 Kit
- Where
- 6 sites in Greece
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Pharmassist Ltd
Non-Small-Cell Lung Carcinoma, Neoplasm Recurrence, Local
A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)
This Phase II, multicenter, randomized trial is designed to make preliminary evaluations of the efficacy of combining bevacizumab with chemotherapy (docetaxel or pemetrexed) or Tarceva relative to chemotherapy (docetaxel or…
- Trial name
- NCT00095225
- Testing
- Avastin (bevacizumab), Tarceva (erlotinib HCl)
- Where
- 48 sites in United States
- Volunteers
- 122 people
- Sponsor
- Genentech, Inc.